US Stock MarketDetailed Quotes
AVXL Anavex Life Sciences
- 9.130
- +0.020+0.22%
Close Nov 25 16:00 ET
- 9.152
- +0.022+0.24%
Post 19:45 ET
774.18MMarket Cap-17901P/E (TTM)
9.786High8.986Low1.70MVolume9.520Open9.110Pre Close15.88MTurnover2.07%Turnover RatioLossP/E (Static)84.80MShares10.45052wk High5.96P/B750.54MFloat Cap3.25052wk Low--Dividend TTM82.21MShs Float31.500Historical High--Div YieldTTM8.78%Amplitude0.600Historical Low9.335Avg Price1Lot Size
About Anavex Life Sciences Company
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
Company Profile
SymbolAVXL
Company NameAnavex Life Sciences
Listing DateOct 28, 2015
Founded2004
CEODr. Christopher U. Missling, PhD
MarketNASDAQ
Employees40
Fiscal Year Ends09-30
Address630 5th Avenue,20th floor
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10111
Phone1-844-689-3939
Websitehttp://www.anavex.com
Company Executives
- Name
- Position
- Salary
- Dr. Christopher U. Missling, PhD
- President, Chief Executive Officer and Director
- 3.89M
- Sandra Boenisch, C.G.A.,C.P.A.
- Principal Financial Officer, Principal Accounting Officer and Treasurer
- 501.06K
- Dr. Jiong Ma, PhD
- Chairman of the Board
- 349.54K
- Athanasios Skarpelos
- Independent Director
- 341.54K
- Dr. Steffen Thomas, PhD
- Independent Director
- 341.54K
- Dr. Peter Donhauser, D.O.
- Independent Director
- 341.54K
- Dr. Claus van der Velden, PhD
- Independent Director
- 357.54K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data